← Back to Search

Tyrosine Kinase Inhibitor

Mivavotinib for Diffuse Large B-Cell Lymphoma

Phase 2
Waitlist Available
Research Sponsored by Calithera Biosciences, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients should not have failed more than 5 prior lines of therapy
Life expectancy of > 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up start of treatment to 21 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it's effective in treating patients with a certain type of aggressive lymphoma. NGS will be used to identify patients who may benefit the most from the drug.

Eligible Conditions
  • MyD88 and CD79B Mutations
  • Diffuse Large B-Cell Lymphoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You cannot have tried more than 5 different treatments before this study.
Select...
You are expected to live for at least 3 more months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~start of treatment to 21 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and start of treatment to 21 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate (ORR) as assessed by an independent radiology review committee (IRC) according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014).
Safety as measured by type, incidence, severity, seriousness, and study drug-relatedness of adverse events per Common Terminology Criteria for Adverse Events, version 5
Secondary outcome measures
Complete Response (CR) Rate as assessed by an IRC according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014).
Duration of Response (DOR) Rate as assessed by an IRC according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014).
Progression-Free Survival (PFS) as assessed by an IRC according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014).

Trial Design

2Treatment groups
Experimental Treatment
Group I: Induction Dosing ScheduleExperimental Treatment1 Intervention
Mivavotinib 120 mg QD for 14 days, then 80 mg QD starting Day 15
Group II: Continuous Dosing ScheduleExperimental Treatment1 Intervention
Mivavotinib 100 mg once daily (QD)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mivavotinib
2019
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

Calithera Biosciences, IncLead Sponsor
33 Previous Clinical Trials
2,019 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does Mivavotinib impact the safety of individuals?

"As the trial is currently in Phase 2, prior evidence of safety has been established but there are no guarantees that mivavotinib will be efficacious. We rate its safety as a 2 on our scale from 1 to 3."

Answered by AI

Are elderly individuals (over 85) being accepted for this clinical investigation?

"Eligibility for this medical trial is limited to adults aged 18-100. Conversely, there are 304 clinical trials available for patients below the age of consent and 1607 studies designated specifically towards seniors over 65 years old."

Answered by AI

Does my profile qualify me for participation in this experiment?

"This medical trial seeks out 50 individuals with b-lymphocytes ranging between 18 and 100 in age. The fundamental requirements for recruitment are; Gender of either male or female, Eastern Cooperative Oncology Group (ECOG) Performance Status rating at 0 to 2, Expectancy of life that exceeds 3 months, Histologically confirmed de novo or transformed non-GCB DLBCL., Relapsed or refractory to ≥ 2 prior lines of chemotherapy based on standard of care, No more than 5 previous treatments failed by the patient, [18F]Fluorodeoxyglucose-positron emission tomography ("

Answered by AI

How extensive is the geographic reach of this experiment?

"Currently, there are 6 clinical trial sites hosting this research. These medical centres are located in Philadelphia, Houston and Evanston among other cities; thus it is wise to choose the nearest option to reduce travel time if you commit to being a participant."

Answered by AI

Are researchers still recruiting for this investigation?

"Affirmative, the clinicaltrials.gov records suggest that this medical experiment is currently recruiting patients. This trial was initiated on June 23rd 2022 and modified most recently on November 7th of the same year. For successful recruitment, 50 individuals need to enrol from 6 dissimilar sites."

Answered by AI

How many applicants are being accepted into the experiment?

"Indeed, the information accessible on clinicaltrials.gov suggests that this trial is actively recruiting patients. This study was unveiled in June of 2022 and its details were most recently revised in November of the same year. The research team seeks to enlist 50 individuals from 6 distinct sites."

Answered by AI
~1 spots leftby Mar 2025